Arjo ABFRA:A39 -1.54%73 PS Ratio is 0.63 as of Jul. 11, 2026, which is 44% below its 10-year median of 1.13. GuruFocus rates FRA:A39 with a GF Score™ of 73/100 and a GF Value™ of €3.25 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 116 Medical Distribution companies, Arjo AB ranks worse than 63.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arjo AB's share price is €2.306.
Arjo AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.65. Hence, Arjo AB's PS Ratio for today is 0.63.
Good Sign:
Arjo AB stock PS Ratio (=0.66) is close to 10-year low of 0.6.
The historical rank and industry rank for Arjo AB's PS Ratio or its related term are showing as below:
FRA:A39'
s PS Ratio Range Over the Past 10 Years
Min: 0.6 Med: 1.13 Max: 3.78
Current: 0.66
During the past 13 years, Arjo AB's highest PS Ratio was 3.78. The lowest was 0.60. And the median was 1.13.
FRA:A39's PS Ratio is ranked worse than 63.79% of 116
companies
in the Medical Distribution industry
Industry Median: 0.405
vs FRA:A39: 0.66
Arjo AB's Revenue per Sharefor the
three
months ended in Mar. 2026 was €0.92.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.65.
Warning Sign:
Arjo AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Arjo AB was -4.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.80% per year.
During the past 13 years, Arjo AB's highest 3-Year average Revenue per Share Growth Rate was 7.60% per year. The lowest was -1.90% per year. And the median was 3.60% per year.
Back to Basics: PS Ratio
Arjo AB (FRA:A39) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Arjo AB PS Ratio Related Terms
Arjo AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Arjo AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Arjo AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Arjo AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Arjo AB's Share Price of today is €2.306. Arjo AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.65.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Arjo AB (FRA:A39) has a PS Ratio of 0.63 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arjo AB and its competitors. This is 44% below median its historical median of 1.13. Over the past decade, Arjo AB's PS Ratio has ranged from 0.60 to 3.78. According to the industry distribution chart, Arjo AB ranks #74 out of 116 companies in the Medical Distribution industry, placing it in the top 63.8%.
Is Arjo AB's PS Ratio too high?
Arjo AB's current PS Ratio of 0.63 is 44% below median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 3.78. The Medical Distribution industry median PS Ratio is 0.41. Arjo AB's value of 0.63 is 55.6% above this industry median. Based on the distribution chart, Arjo AB ranks #74 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Arjo AB has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's PS Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #74 out of 116 companies for PS Ratio. This places Arjo AB in the lower half of its industry. The industry median PS Ratio is 0.41. Arjo AB's value of 0.63 is 55.6% above this benchmark. Historically, Arjo AB's own PS Ratio has ranged from 0.60 to 3.78 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 0.41, Arjo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.41, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current PS Ratio of 0.63 is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current PS Ratio is 0.63, which is 44% below median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.25, compared to a current price of €2.31 — trading 29% below its estimated fair value. The current PS Ratio is 0.63, which is 44% below median its 10-year median of 1.13 and 55.6% above the Medical Distribution industry median of 0.41. Arjo AB's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current PS Ratio is 0.63 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.31 is trading 29% below its estimated GF Value™ of €3.25.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for FRA:A39:
PS Ratio: 0.63 (44% below median its 10-year median of 1.13)
GF Value™: €3.25 vs. price of €2.31 (29% below fair value)
Industry Position: 55.6% above the Medical Distribution median (#74 of 116)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
73GF Score
Get the complete analysis for FRA:A39
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
